Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
17 hedge funds and large institutions have $35.6M invested in Cymabay Therapeutics in 2014 Q3 according to their latest regulatory filings, with 17 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
+$7.68M |
| 2 |
Jennison Associates
New York
|
+$6.15M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
+$4.35M |
| 4 |
DM
Deerfield Management
New York
|
+$3.15M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$3.01M |
Top Sellers
CBAY Hedge Fund Activity: Q3 2014 in Review
17 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q3 2014, worth a combined $35.6M.
Buyers outnumbered sellers: 17 funds opened new CBAY positions and 0 closed out — a net gain of 17 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Lombard Odier Asset Management (USA), opening a new position worth an estimated $7.68M.
- 17 institutional investors held Cymabay Therapeutics (CBAY) as of Q3 2014, up from 0 in Q2 2014.
- Funds reported $35.6M of Cymabay Therapeutics stock for Q3 2014.
- 17 funds opened new Cymabay Therapeutics positions in Q3 2014 and 0 closed out, a net change of +17 holders.
- The largest Cymabay Therapeutics buyer in Q3 2014 was Lombard Odier Asset Management (USA), an estimated $7.68M added.
Based on aggregated 13F filings for Q3 2014.